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~ynovial fluid F~~ronectin Sialic acid deficiency 
1, INTRODUCTION fibronectin by proteolytic enzymes present in 
synovial fluid [lo]. 
Fibronectins are high h4, glycoproteins present 
in an insoluble form in int~rstiti~ matrices, base- 
ment membranes, newly formed connective tissue, 
differentiating cartilage and bone, and rheumatoid 
synovial membrane. Fibronectins are also present, 
in a soluble form, in blood plasma and other body 
fluids including amniotic, synovial, cerebrospinal 
and pleural fluids, urine and milk (for reviews on 
distribution, structure and biological functions of 
fibronectin see [l-6]). 
Here we demonstrate that charge differences 
between plasma and synovial fluid fibronectin are 
not due to proteolytic cleavage but to lack of sialic 
acid in synovial fluid fibronectin. 
2. MATERIALS AND METHODS 
The functions attributed to fibronectin such as 
cell adhesion to substrata, cell spreading, op- 
sonization of bacteria and other particulate mat- 
ter, ability to induce a more normal phenotype in 
transformed cells, wound healing and chemotaxis 
are all related to its affinity to cell surface and a 
large number of different macromolecules (see 
reviews above). 
In previous studies fibron~ctin has been reported 
to be present in synovial fluid from patients with 
various rheumatic diseases and exceed those in 
plasma samples from the same individual, sug- 
gesting local synthesis [7-lo]. 
Recently it was reported that synovial fluid 
~bronectin from rheumatoid patients has a dif- 
ferent molecular charge with respect to plasma 
fibronectin [lo]. This different molecular charge 
has been attributed to proteolytic cleavage of 
Synovial fluid and blood were supplemented 
with EDTA (final cont. 0.590, w/v). Synovial 
fluids were incubated with hyaluronidase (final 
cont. 5 pg/ml) at 37°C for 1 h. Samples were cen- 
trifuged at 7000 x g for 10 min at 20°C. Sodium 
azide at a final cont. of 0.1% (w/v) and 
5 kunits/ml of aprotinin (Sigma, St. Louis, MO) 
were added. In experiments comparing plasma and 
synovial fluid fibronectin the plasma was also in- 
cubated with hyaluronidase (5 @g/ml). Human 
plasma and synovial fluid fibronectin were 
purified as in [ 11,121. Sodium dodecylsulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) 
was done as in [ 131. Separation of plasma and 
synovial fluid proteins according to their net 
molecular charge was carried out either on 5% 
polyacrylamide gels as in [f4] or on 2% agarose in 
high resolution buffer (Gelman Sciences, Ann Ar- 
bor, MI). 
* To whom reprint requests should be addressed 
plasma and synovial fluid proteins were 
transferred from polyacrylamide gels to 
nitrocellulose sheets as in [ 151. Fibronectin was 
located on nitrocellulose sheets using monospecific 
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rabbit antibodies to human plasma fibronectin and 
peroxidase conjugated goat anti-rabbit Ig as the se- 
cond antibody [ 15,161. 
Neuraminidase (Neuraminidase-Test, Beh- 
ringwerke, Marburg, FRG) treatment of purified 
plasma and synovial fluid fibronectin was carried 
out incubating fibronectin (0.5 mg/ml final cont.) 
in 0.05 M sodium acetate buffer, 0.154 M NaCl, 
9 mM CaClz (pH 5.5) with neuraminidase 
(0.5 units/ml final cont.) for 1 h at 37°C. 
Thermolysin (Protease type X, Sigma, St. Louis, 
MO) digestion of purified fibronectin was per- 
formed as in [ 171. Purified fibronectin (1 mg/ml) 
in 25 mM Tris (pH 7.6), 0.5 mM EDTA, 50 mM 
NaCl was digested with 5 pg/ml thermolysin for 
4 h at 22°C. The digestion was terminated by ad- 
ding EDTA (5 mM final cont.) to inactivate ther- 
molysin. Purification of the gelatin binding 
fragments from the fibronectin thermolysin digest 
was carried out as in [ 171. 
3. RESULTS 
Fig.lA shows an SDS-PAGE of purified 
plasma and synovial fluid fibronectin; no signifi- 
cant differences in apparent M, are detectable. No 
fibronectin fragments are visible in either fibronec- 
tin preparation. Identical results were obtained 
with fibronectin from synovial fluid from healthy 
donors or from patients suffering from inflam- 
matory rheumatic diseases. To exclude the 
possibility of artifacts or selection of fibronectin 
molecules during the purification procedures total 
plasma and synovial fluid proteins were trans- 
ferred from a 10% SDS-PAGE onto a 
nitrocellulose sheet followed by immunoenzymatic 
localization of fibronectin. Results identical to 
those observed with purified fibronectin were ob- 
tained (fig.lB). 
Fig.2 shows an agarose gel electrophoresis on 
which purified plasma and synovial fluid fibronec- 
tin, before and after neuraminidase treatment, 
migrated according to their net molecular charge. 
Before neuraminidase treatment synovial fluid 
fibronectin shows a slower mobility with respect o 
plasma fibronectin. Neuraminidase treatment does 
not change the mobility of synovial fluid fibronec- 
tin. In contrast, after neuraminidase treatment, 
plasma fibronectin assumes a mobility identical to 
that of synovial fluid fibronectin. These data in- 
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Fig. 1. (A) 10% SDS-PAGE of plasma (1) and synovial 
fluid (2) fl-mercaptoethanol reduced purified 
fibronectin. (B) Nitrocellulose strip on which plasma (3) 
and synovial fluid (4) proteins were transferred after 
separation on 10% SDS-PAGE followed by 
immunoenzymic localization of fibronectin. 
dicate that synovial fluid fibronectin lacks sialic 
acid. 
To determine which domain(s) of synovial fluid 
fibronectin lacks sialic acid, neuraminidase-treated 
and untreated plasma and synovial fluid fibronec- 
tin were digested by thermolysin and the polypep- 
tides obtained analysed on polyacrylamide gel 
electrophoresis. 
Fig.3 shows thermolysin digests of neuramin- 
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Fig-Z. 2% agarose geI of purified fibronectin from: 
plasma (1); synovial fluid (2); pIasma after 
neuraminidase treatment (3); synovial fluid after 
neuraminidase tr atment (4). 
idase-treated and untreated plasma and synovial 
fluid fibronectin separated on a 5% polyacryl- 
amide gel electrophoresis according to net 
molecular charge. Thermolysin digest of neur- 
ami~dase-untreated plasma fibronectin shows 
many polypeptides with a higher electrophoretic 
mobility with respect to those of synovial fluid 
fibronectin thermolysin digest (fig.3, lanes 1,2). 
Thermolysin digest of neuraminidase-treated 
plasma fibronectin shows a pattern identical to 
Fig.3. 5% PAGE of thermolysin digested purified 
plasma and synovial fluid fibronectin. Lane 1, 
thermolysin digestion of synovial fluid fibronectin, lane 
2, thermolysin digestion of plasma fibronectin, lane 3. 
thermolysin digestion of synovial fluid fibronectin 
previously treated with neuraminidase, lane 4, 
thermolysin digestion of plasma fibronectin previously 
treated with neuraminidase, lane 5, thermolysin digest 
purified plasma gelatin binding fibronectin fragment, 
lane 6, thermolysin digest purified plasma gelatin 
binding fragment after neuraminidase treatment. 
that of synovial fluid fibronectin (fig.3, lanes 3,4). 
In contrast, the patterns of the thermolysin digests 
of neur~inidase-treated and untreated synovial 
fluid fibronectin are identical (fig.3, 
Fig.3 also shows the purified plasma 
gelatin binding fragment before 
neuraminidase treatment (lanes 5,6). 
lanes I ,3). 
fibronectin 
and after 
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4. DISCUSSION REFERENCES 
Synovial fluid fibronectin does not show detec- 
table differences in its apparent M, with respect o 
plasma fibronectin as determined by SDS-PAGE. 
This is observed with fibronectin from the synovial 
fluid of healthy donors and patients suffering from 
rheumatic inflammatory diseases [181. In contrast, 
all synovial fluid fibronectins show a different net 
molecular charge compared with plasma fibronec- 
tins. This difference in molecular charge cannot be 
explained by proteolytic cleavage of synovial fluid 
fibronectin, as suggested in [lo], since synovial 
fluid fibronectin shows an I%& similar to that of 
plasma fibronectin. 
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Here we demonstrate that the difference bet- 
ween the electrophoretic mobility of synovial fluid 
and plasma fibronectin is due to a lack of sialic 
acid in synovial fluid fibronectin. Furthermore, 
neuraminidase treatment of thermolysin digest 
fragments indicates that the synovial fluid gelatin 
binding fragment is completely lacking in sialic 
acid. The different sialic acid content of synovial 
fluid fibronectin may be due to synthesis by a cell 
type which differs from that responsible for the 
production of the plasmatic pool. Hepatocytes 
have been proposed as the major producers of 
plasma fibronectin [19]. Likely candidates for the 
production of synovial fluid fibronectin, which is 
at least in part locally synthesized [7-lo], would 
include endothelial cells and synoviocytes. Studies 
on the electrophoretic mobility of fibronectins syn- 
thesized by different kinds of cultured cells should 
clarify the origin of synovial fluid fibronectin. 
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